Redeye initiates coverage of NeuroVive, a high-risk case with a promising early-stage portfolio in primary mitochondrial diseases. While previous high-profile failures and dilutive rights issues have hurt the company’s standing, the share’s huge decline has taken valuation to undemanding levels – though nearer-term catalysts are few and the current capital raising may weigh on performance.